NASDAQ · Biotechnology

Immatics N.V. (IMTX) Stock

$7.31 -3.05% NASDAQ: IMTX Healthcare

Valuation

MetricValue
Price$7.31
Market Cap$1.09B
P/E Ratio-4.33
P/B Ratio2.36
P/S Ratio22.14
EPS (TTM)$-1.78
52-Week High$12.41
52-Week Low$6.70
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-47.04%
ROA-42.54%
ROCE-52.91%
Gross Margin100.00%
Operating Margin-5.70%
Net Margin-495.27%
Debt/Equity0.04
Current Ratio11.72

Annual Financials (USD)

Metric20212022202320242025
Revenue$35.0M$173.0M$54.0M$156.0M$48.0M
Operating Profit$-86.0M$30.0M$-102.0M$-39.0M$-182.0M
Net Profit$-93.0M$28.0M$-95.0M$15.0M$-196.0M
EPS$-1.48$0.55$-1.18$0.14$-1.54
Op Margin-248.2%17.3%-188.4%-24.8%-377.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$175.0M$408.0M$510.0M$696.0M$562.0M
Total Liabilities$151.0M$204.0M$292.0M$121.0M$78.0M
Cash$133.0M$149.0M$218.0M$237.0M$346.0M
Borrowings$10.0M$15.0M$15.0M$16.0M$16.0M

Latest News

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting GlobeNewswire · Jun 1, 2026 Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer GlobeNewswire · May 31, 2026 Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting GlobeNewswire · May 30, 2026 Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results Simply Wall St. · May 15, 2026 Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates Zacks · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-82.0M$100.0M$18.0M$-158.0M$-170.0M
Investing Cash Flow$2.0M$-216.0M$-62.0M$-169.0M$190.0M
Financing Cash Flow$0$-8.0M$-2.0M$-21.0M$-3.0M
Net Cash Flow$-75.0M$16.0M$70.0M$18.0M$137.0M
Free Cash Flow$-87.0M$94.0M$-13.0M$-175.0M$-176.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.05
EV / EBITDA-3.64
FCF Yield-22.74%
Quick Ratio7.54
Interest Coverage-261.27
Return 1Y44.03%
Return 3Y-23.79%
Return 5Y-21.56%

Ownership

Insiders Held17.58%
Institutions Held79.47%
Institutions Float Held96.42%
Institutional HolderSharesReport Date
T. Rowe Price Investment Management, Inc.21,652,1622026-03-31
RTW Investments LP12,869,3402026-03-31
Suvretta Capital Management, LLC11,190,1292026-03-31
Baker Bros. Advisors, LP10,916,6932026-03-31
Perceptive Advisors Llc10,383,4562026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALLOAllogene Therapeutics, Inc. $1.25 +0.00% -2.24 $431.86M 0.00%
ATRAAtara Biotherapeutics, Inc. $8.59 -8.91% -7.94 $86.22M 0.00%
BNTXBioNTech SE $90.07 -1.55% -15.45 $22.78B 0.00%
CLLSCellectis S.A. $2.81 -2.26% -4.14 $282.17M 0.00%
DTILPrecision BioSciences, Inc. $6.64 -2.06% -2.26 $183.27M 0.00%

About Immatics N.V.

Immatics N.V. is led by CEO Harpreet Singh, employs 554 people, headquartered in DE, publicly traded since 2018.

Immatics N.V. (IMTX) stock trades at $7.31 with a market capitalization of $1.09B. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.33, reflecting a net loss over the last twelve months, price-to-book of 2.36, price-to-sales of 22.14. Over the past 52 weeks the stock has ranged between $6.70 and $12.41, and currently trades 41.1% below its 52-week high.

On profitability, Immatics N.V. generates a return on equity (ROE) of -47.04% (negative, reflecting a net loss), return on capital employed of -52.91%, an operating margin of -5.70%, a net profit margin of -495.27%.

Immatics N.V. by the numbers, 2018–2025

Between 2018 and 2025 Immatics N.V. reported revenue of $4.0M rising to $48.0M, a change of +1100.0% across 8 years. Compounded, revenue has grown 9.1% a year over five years, -34.8% over three, -69.2% over the last twelve months. Net profit fell to $-196.0M.

Operating margin went from -912.7% in 2018 to -377.1% in 2025, a gain of 535.6 percentage points. The most recent net margin is -495.27%. On a trailing twelve-month basis to Jun '26, revenue is $42.0M and net profit $-207.0M.

Borrowings stand at $16.0M, cash from operations was $-170.0M in the latest year, positive in 4 of the last 8.

Return on equity has averaged -91.0% over five years, and was -40.5% in the most recent year.

The share price itself has compounded at -4.4% a year over five years, -9.5% over three, 54.0% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Immatics N.V. (IMTX) — frequently asked questions

What is Immatics N.V. (IMTX) stock price today?

Immatics N.V. (IMTX) is currently trading at $7.31, down 3.05% today.

What is IMTX P/E ratio?

Immatics N.V.'s P/E ratio is -4.33. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is IMTX return on equity (ROE)?

Immatics N.V.'s return on equity (ROE) is -47.04%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Immatics N.V.'s market cap?

Immatics N.V. has a market capitalization of $1.09B.

Does IMTX pay a dividend?

Immatics N.V. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does IMTX carry?

Immatics N.V. has a debt-to-equity ratio of 0.04. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is IMTX's profit margin?

Immatics N.V. reports a net profit margin of -495.27% — the share of revenue left after every cost, including tax and interest.

What sector is IMTX in?

Immatics N.V. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is IMTX listed on?

Immatics N.V. trades on NASDAQ under the ticker IMTX.

What is IMTX's 52-week range?

Over the last year Immatics N.V. has traded between $6.70 and $12.41.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens IMTX currently matches

On the figures above, Immatics N.V. passes the filters for 10 of our ready-made screens, among them Low Debt Stocks, Small Cap Stocks, Stocks Under $10. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Low Debt StocksSmall Cap StocksStocks Under $10Debt Free Stocks Under $100Debt Free StocksStocks Under $100Stocks Under $50High Gross Margin StocksDebt to Equity Below 1 StocksHigh Current Ratio Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.